{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:09:01Z","timestamp":1778818141410,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00198-025-07756-y","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:38:34Z","timestamp":1763545114000},"page":"167-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment patterns of romosozumab in postmenopausal women with severe osteoporosis in Denmark: findings from the ROmosozumab in Scandinavia real-world Evidence\u00a0Study (ROSES)"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-7199","authenticated-orcid":false,"given":"Bente L.","family":"Langdahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattias","family":"Lorentzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tove T.","family":"Borgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estelle","family":"Bajtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Kaarill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilie","family":"Alstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Rieem Dun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mie Sisse","family":"Konradsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Liseth Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oskar","family":"Str\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Tsitlakidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Moayyeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"8","key":"7756_CR1","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9(8):1137\u20131141. https:\/\/doi.org\/10.1002\/jbmr.5650090802","journal-title":"J Bone Miner Res"},{"issue":"11","key":"7756_CR2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48582","volume":"15","author":"SH Charde","year":"2023","unstructured":"Charde SH, Joshi A, Raut J (2023) A Comprehensive Review on Postmenopausal Osteoporosis in Women. Cureus 15(11):e48582. https:\/\/doi.org\/10.7759\/cureus.48582","journal-title":"Cureus"},{"issue":"6","key":"7756_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/bf01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4(6):368\u2013381. https:\/\/doi.org\/10.1007\/bf01622200","journal-title":"Osteoporos Int"},{"issue":"4","key":"7756_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/joim.12873","volume":"285","author":"M Lorentzon","year":"2019","unstructured":"Lorentzon M (2019) Treating osteoporosis to prevent fractures: current concepts and future developments. J Intern Med 285(4):381\u2013394. https:\/\/doi.org\/10.1111\/joim.12873","journal-title":"J Intern Med"},{"issue":"6","key":"7756_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/00325481.2022.2069582","volume":"134","author":"MR McClung","year":"2022","unstructured":"McClung MR, Rothman MS, Lewiecki EM, Hanley DA, Harris ST, Miller PD et al (2022) The role of osteoanabolic agents in the management of patients with osteoporosis. Postgrad Med 134(6):541\u2013551. https:\/\/doi.org\/10.1080\/00325481.2022.2069582","journal-title":"Postgrad Med"},{"issue":"9","key":"7756_CR6","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/jbmr.3735","volume":"34","author":"P Chavassieux","year":"2019","unstructured":"Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP et al (2019) Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J Bone Miner Res 34(9):1597\u20131608. https:\/\/doi.org\/10.1002\/jbmr.3735","journal-title":"J Bone Miner Res"},{"key":"7756_CR7","doi-asserted-by":"publisher","unstructured":"Weiser M, Johns W, Hozack B (2024) Osteoporosis Treatment Strategies: Current Concepts. SurgiColl 2(2). https:\/\/doi.org\/10.58616\/001c.84133","DOI":"10.58616\/001c.84133"},{"issue":"1","key":"7756_CR8","doi-asserted-by":"publisher","first-page":"R9","DOI":"10.1093\/ejendo\/lvae076","volume":"191","author":"AD Anastasilakis","year":"2024","unstructured":"Anastasilakis AD, Yavropoulou MP, Palermo A, Makras P, Paccou J, Tabacco G et al (2024) Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when? Eur J Endocrinol 191(1):R9-r21. https:\/\/doi.org\/10.1093\/ejendo\/lvae076","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"7756_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jbmr.3051","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32(2):198\u2013202. https:\/\/doi.org\/10.1002\/jbmr.3051","journal-title":"J Bone Miner Res"},{"issue":"5\u20136","key":"7756_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/1759720x18775936","volume":"10","author":"ASK S\u00f8lling","year":"2018","unstructured":"S\u00f8lling ASK, Harsl\u00f8f T, Langdahl B (2018) The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis 10(5\u20136):105\u2013115. https:\/\/doi.org\/10.1177\/1759720x18775936","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"11","key":"7756_CR11","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1002\/jbmr.4409","volume":"36","author":"JP Brown","year":"2021","unstructured":"Brown JP, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes AJ et al (2021) Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the active-controlled fracture study in postmenopausal women with osteoporosis at high risk (ARCH) trial. J Bone Miner Res 36(11):2139\u20132152. https:\/\/doi.org\/10.1002\/jbmr.4409","journal-title":"J Bone Miner Res"},{"key":"7756_CR12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.bone.2015.07.036","volume":"81","author":"C Graeff","year":"2015","unstructured":"Graeff C, Campbell GM, Pe\u00f1a J, Borggrefe J, Padhi D, Kaufman A et al (2015) Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis. Bone 81:364\u2013369. https:\/\/doi.org\/10.1016\/j.bone.2015.07.036","journal-title":"Bone"},{"key":"7756_CR13","unstructured":"European Medicines Agency (EMA) (2020) Evenity (romosozumab). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evenity. Accessed 1 July 2024"},{"key":"7756_CR14","unstructured":"Medicinr\u00e5det: Romosozumab (Evenity) (2020) https:\/\/medicinraadet.dk\/anbefalinger-og-vejledninger\/laegemidler-og-indikationsudvidelser\/r\/romosozumab-evenity-behandling-af-svaer-osteoporose-hos-postmenopausale-kvinder-med-hoj-risiko-for-fraktur . Accessed 1 Dec 2024"},{"issue":"15","key":"7756_CR15","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"issue":"16","key":"7756_CR16","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"issue":"12","key":"7756_CR17","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1007\/s00198-022-06544-2","volume":"33","author":"B Langdahl","year":"2022","unstructured":"Langdahl B, Hofbauer LC, Ferrari S, Wang Z, Fahrleitner-Pammer A, Gielen E et al (2022) Romosozumab efficacy and safety in European patients enrolled in the FRAME trial. Osteoporos Int 33(12):2527\u20132536. https:\/\/doi.org\/10.1007\/s00198-022-06544-2","journal-title":"Osteoporos Int"},{"key":"7756_CR18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae484","author":"MC Hartz","year":"2024","unstructured":"Hartz MC, Johannessen FB, Harsl\u00f8f T, Langdahl BL (2024) The effectiveness and safety of romosozumab and teriparatide in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae484","journal-title":"J Clin Endocrinol Metab"},{"key":"7756_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-024-01530-6","author":"S Soen","year":"2024","unstructured":"Soen S, Wang A, Hamaya E, Chien HC, Lin TC (2024) Drug utilization pattern of romosozumab and other osteoporosis treatments in Japan, 2019\u20132021. J Bone Miner Metab. https:\/\/doi.org\/10.1007\/s00774-024-01530-6","journal-title":"J Bone Miner Metab"},{"issue":"9","key":"7756_CR20","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s00198-024-07155-9","volume":"35","author":"J Everts-Graber","year":"2024","unstructured":"Everts-Graber J, Wenger M, Oser S, Studer U, Steiner C, Ziswiler HR et al (2024) The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland. Osteoporos Int 35(9):1605\u20131613. https:\/\/doi.org\/10.1007\/s00198-024-07155-9","journal-title":"Osteoporos Int"},{"issue":"5","key":"7756_CR21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.eprac.2024.01.014","volume":"30","author":"F Cosman","year":"2024","unstructured":"Cosman F, Langdahl B, Leder BZ (2024) Treatment sequence for osteoporosis. Endocr Pract 30(5):490\u2013496. https:\/\/doi.org\/10.1016\/j.eprac.2024.01.014","journal-title":"Endocr Pract"},{"issue":"1","key":"7756_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2018","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2018) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3\u201344. https:\/\/doi.org\/10.1007\/s00198-018-4704-5","journal-title":"Osteoporos Int"},{"issue":"1","key":"7756_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jbmr.4433","volume":"37","author":"R Eastell","year":"2022","unstructured":"Eastell R, Vittinghoff E, Lui LY, McCulloch CE, Pavo I, Chines A et al (2022) Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project. J Bone Miner Res 37(1):29\u201335. https:\/\/doi.org\/10.1002\/jbmr.4433","journal-title":"J Bone Miner Res"},{"key":"7756_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00774-023-01477-0","volume":"42","author":"A Miyauchi","year":"2024","unstructured":"Miyauchi A, Hamaya E, Shimauchi J, Yoshinaga Y, Nishi K (2024) Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study. J Bone Miner Metab 42:77\u201389. https:\/\/doi.org\/10.1007\/s00774-023-01477-0","journal-title":"J Bone Miner Metab"},{"issue":"10","key":"7756_CR25","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ et al (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33(10):2049\u20132102. https:\/\/doi.org\/10.1007\/s00198-021-05900-y","journal-title":"Osteoporos Int"},{"key":"7756_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/20420188221112904","volume":"13","author":"R Palui","year":"2022","unstructured":"Palui R, Durgia H, Sahoo J, Naik D, Kamalanathan S (2022) Timing of osteoporosis therapies following fracture: the current status. Ther Adv Endocrinol Metab 13:20420188221112904. https:\/\/doi.org\/10.1177\/20420188221112904","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"7756_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-020-00774-9","volume":"15","author":"MF Hitz","year":"2020","unstructured":"Hitz MF, Arup S, Holm JP, Soerensen AL, Gerds TA, Jensen J-EB (2020) Outcome of osteoporosis evaluation, treatment, and follow-up in patients referred to a specialized outpatient clinic compared to patients in care of general practitioners. Arch Osteoporos 15(1):97. https:\/\/doi.org\/10.1007\/s11657-020-00774-9","journal-title":"Arch Osteoporos"},{"issue":"4","key":"7756_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00223-018-0437-x","volume":"103","author":"N Napoli","year":"2018","unstructured":"Napoli N, Langdahl BL, Ljunggren \u00d6, Lespessailles E, Kapetanos G, Kocjan T et al (2018) Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European Extended Forsteo\u00ae Observational Study (ExFOS). Calcif Tissue Int 103(4):359\u2013371. https:\/\/doi.org\/10.1007\/s00223-018-0437-x","journal-title":"Calcif Tissue Int"},{"issue":"9999","key":"7756_CR29","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386(9999):1147\u20131155. https:\/\/doi.org\/10.1016\/s0140-6736(15)61120-5","journal-title":"Lancet"},{"issue":"6","key":"7756_CR30","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A et al (2022) Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int 33(6):1243\u20131256. https:\/\/doi.org\/10.1007\/s00198-021-06174-0","journal-title":"Osteoporos Int"},{"key":"7756_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116954","volume":"178","author":"Y Liu","year":"2024","unstructured":"Liu Y, Arora T, Zhang J, Sodhi SK, Xie F, Curtis JR (2024) The interruption of romosozumab treatment during COVID lockdown among US post-menopausal women enrolled in Medicare. Bone 178:116954. https:\/\/doi.org\/10.1016\/j.bone.2023.116954","journal-title":"Bone"},{"issue":"2","key":"7756_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/pds.5544","volume":"32","author":"SS Janjua","year":"2023","unstructured":"Janjua SS, Boardman HF, Sami A, Johansen A, Toh LS, Javaid KM (2023) Anti-osteoporosis medication dispensing by clinical commissioning groups in England - an ecological study of variability in practice and of the effect of the Covid-19 pandemic. Pharmacoepidemiol Drug Saf 32(2):248\u2013255. https:\/\/doi.org\/10.1002\/pds.5544","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07756-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07756-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07756-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:37:51Z","timestamp":1769510271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07756-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7756"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07756-y","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the results presented in this article are in aggregate form and no personally identifiable information was used for this study. For this type of study formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Bente L. Langdahl declares having received fees and honoraria for lectures and advice from Amgen, Astellas, Astra-Zeneca, Gedeon-Richter, Samsung-Bioepis, Mereo, Angitia\u00a0and UCB. Mattias Lorentzon declares having received lecture fees from Amgen, Astellas, Lilly, Meda, Medison, Consilient Health and UCB in addition to consulting fees from Amgen, Medac AB, Pharmacosmos, Gedeon Richter, Parexel International, and UCB. Tove T. Borgen declares having received speaker fees from Amgen, Roche Diagnostics, Pharma Prim and UCB, and participation in the advisory board for UCB. Cecilie Alstad is a former employee and stockholder of UCB. Estelle Bajtner is an employee and stockholder of UCB. Alexander Rieem Dunn is a former employee of Quantify Research, a contract research organization that provides consultancy services to the pharmaceutical industry. Tanja Kaarill is an employee of UCB. Mie Sisse Konradsen is a former employee of Quantify Research, a contract research organization that provides consultancy services to the pharmaceutical industry. Evangelos Tsitlakidis is a Significance consultant for UCB. Johan Liseth Hansen is an employee of Quantify Research, a contract research organization that provides consultancy services to the pharmaceutical industry. Oskar Str\u00f6m is an employee of Quantify Research, a contract research organization that provides consultancy services to the pharmaceutical industry. Ali Moayyeri is an employee and stockholder of UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Data used in this study cannot be shared freely as it is the property of the Danish data holders. Other parties can request the same data sources and content by submitting new data applications to the data holders. The terms for using the data are governed by data holder approval subject to data application.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}}]}}